vs
HCI Group, Inc.（HCI）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
HCI Group, Inc.的季度营收约是Orthofix Medical Inc.的1.1倍（$242.9M vs $219.9M），HCI Group, Inc.净利率更高（35.0% vs -1.0%，领先36.0%），HCI Group, Inc.同比增速更快（12.2% vs 2.0%），过去两年HCI Group, Inc.的营收复合增速更高（8.5% vs 8.0%）
HCI集团是一家总部位于美国华盛顿特区的私募股权投资公司，在伊利诺伊州芝加哥设有分支机构，专注于股权投资相关业务，为合作企业提供资本支持与运营赋能，助力企业实现长期发展目标。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
HCI vs OFIX — 直观对比
营收规模更大
HCI
是对方的1.1倍
$219.9M
营收增速更快
HCI
高出10.2%
2.0%
净利率更高
HCI
高出36.0%
-1.0%
两年增速更快
HCI
近两年复合增速
8.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $242.9M | $219.9M |
| 净利润 | $85.0M | $-2.2M |
| 毛利率 | — | 71.1% |
| 营业利润率 | — | 0.2% |
| 净利率 | 35.0% | -1.0% |
| 营收同比 | 12.2% | 2.0% |
| 净利润同比 | 14.6% | 92.4% |
| 每股收益（稀释后） | $5.45 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HCIOFIX
| Q1 26 | $242.9M | — | ||
| Q4 25 | $246.2M | $219.9M | ||
| Q3 25 | $216.3M | $205.6M | ||
| Q2 25 | $221.9M | $203.1M | ||
| Q1 25 | $216.4M | $193.6M | ||
| Q4 24 | $161.9M | $215.7M | ||
| Q3 24 | $175.3M | $196.6M | ||
| Q2 24 | $206.2M | $198.6M |
净利润HCIOFIX
| Q1 26 | $85.0M | — | ||
| Q4 25 | $97.7M | $-2.2M | ||
| Q3 25 | $65.5M | $-22.8M | ||
| Q2 25 | $66.2M | $-14.1M | ||
| Q1 25 | $69.7M | $-53.1M | ||
| Q4 24 | $2.6M | $-29.1M | ||
| Q3 24 | $5.7M | $-27.4M | ||
| Q2 24 | $54.1M | $-33.4M |
毛利率HCIOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | 71.1% | ||
| Q3 25 | — | 72.2% | ||
| Q2 25 | — | 68.7% | ||
| Q1 25 | — | 62.8% | ||
| Q4 24 | — | 69.0% | ||
| Q3 24 | — | 68.7% | ||
| Q2 24 | — | 67.8% |
营业利润率HCIOFIX
| Q1 26 | — | — | ||
| Q4 25 | 58.5% | 0.2% | ||
| Q3 25 | 41.9% | -8.3% | ||
| Q2 25 | 42.5% | -7.9% | ||
| Q1 25 | 46.4% | -25.2% | ||
| Q4 24 | 3.6% | -5.3% | ||
| Q3 24 | 8.0% | -9.6% | ||
| Q2 24 | 36.9% | -12.5% |
净利率HCIOFIX
| Q1 26 | 35.0% | — | ||
| Q4 25 | 39.7% | -1.0% | ||
| Q3 25 | 30.3% | -11.1% | ||
| Q2 25 | 29.8% | -6.9% | ||
| Q1 25 | 32.2% | -27.4% | ||
| Q4 24 | 1.6% | -13.5% | ||
| Q3 24 | 3.2% | -13.9% | ||
| Q2 24 | 26.2% | -16.8% |
每股收益（稀释后）HCIOFIX
| Q1 26 | $5.45 | — | ||
| Q4 25 | $7.29 | $-0.05 | ||
| Q3 25 | $4.90 | $-0.57 | ||
| Q2 25 | $5.18 | $-0.36 | ||
| Q1 25 | $5.35 | $-1.35 | ||
| Q4 24 | $0.32 | $-0.76 | ||
| Q3 24 | $0.52 | $-0.71 | ||
| Q2 24 | $4.24 | $-0.88 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.0B | $82.0M |
| 总债务越低越好 | $31.7M | — |
| 股东权益账面价值 | $1.1B | $450.0M |
| 总资产 | $2.6B | $850.6M |
| 负债/权益比越低杠杆越低 | 0.03× | — |
8季度趋势，按日历期对齐
现金及短期投资HCIOFIX
| Q1 26 | $1.0B | — | ||
| Q4 25 | $1.2B | $82.0M | ||
| Q3 25 | $987.9M | $62.9M | ||
| Q2 25 | $947.2M | $65.6M | ||
| Q1 25 | $754.5M | $58.0M | ||
| Q4 24 | $532.5M | $83.2M | ||
| Q3 24 | $518.8M | $30.1M | ||
| Q2 24 | $445.8M | $26.4M |
总债务HCIOFIX
| Q1 26 | $31.7M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $157.2M | ||
| Q2 25 | — | $157.0M | ||
| Q1 25 | — | $156.9M | ||
| Q4 24 | — | $157.0M | ||
| Q3 24 | — | $118.5M | ||
| Q2 24 | — | $118.0M |
股东权益HCIOFIX
| Q1 26 | $1.1B | — | ||
| Q4 25 | $1.0B | $450.0M | ||
| Q3 25 | $821.8M | $442.5M | ||
| Q2 25 | $758.6M | $458.3M | ||
| Q1 25 | $522.7M | $458.3M | ||
| Q4 24 | $453.3M | $503.1M | ||
| Q3 24 | $455.3M | $525.9M | ||
| Q2 24 | $447.3M | $546.0M |
总资产HCIOFIX
| Q1 26 | $2.6B | — | ||
| Q4 25 | $2.5B | $850.6M | ||
| Q3 25 | $2.3B | $832.6M | ||
| Q2 25 | $2.4B | $837.2M | ||
| Q1 25 | $2.3B | $823.1M | ||
| Q4 24 | $2.2B | $893.3M | ||
| Q3 24 | $2.0B | $867.9M | ||
| Q2 24 | $1.9B | $882.0M |
负债/权益比HCIOFIX
| Q1 26 | 0.03× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.34× | ||
| Q4 24 | — | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.22× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $27.7M |
| 自由现金流经营现金流 - 资本支出 | — | $16.8M |
| 自由现金流率自由现金流/营收 | — | 7.6% |
| 资本支出强度资本支出/营收 | — | 4.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-1.3M |
8季度趋势，按日历期对齐
经营现金流HCIOFIX
| Q1 26 | — | — | ||
| Q4 25 | $444.4M | $27.7M | ||
| Q3 25 | $26.7M | $12.4M | ||
| Q2 25 | $145.0M | $11.6M | ||
| Q1 25 | $162.0M | $-18.4M | ||
| Q4 24 | $331.8M | $23.7M | ||
| Q3 24 | $104.1M | $11.7M | ||
| Q2 24 | $-29.0M | $9.0M |
自由现金流HCIOFIX
| Q1 26 | — | — | ||
| Q4 25 | $440.8M | $16.8M | ||
| Q3 25 | $25.9M | $2.5M | ||
| Q2 25 | $144.5M | $4.5M | ||
| Q1 25 | $160.3M | $-25.1M | ||
| Q4 24 | $327.8M | $15.2M | ||
| Q3 24 | $103.2M | $6.3M | ||
| Q2 24 | $-30.1M | $-360.0K |
自由现金流率HCIOFIX
| Q1 26 | — | — | ||
| Q4 25 | 179.0% | 7.6% | ||
| Q3 25 | 12.0% | 1.2% | ||
| Q2 25 | 65.1% | 2.2% | ||
| Q1 25 | 74.1% | -13.0% | ||
| Q4 24 | 202.5% | 7.0% | ||
| Q3 24 | 58.9% | 3.2% | ||
| Q2 24 | -14.6% | -0.2% |
资本支出强度HCIOFIX
| Q1 26 | — | — | ||
| Q4 25 | 1.5% | 4.9% | ||
| Q3 25 | 0.4% | 4.8% | ||
| Q2 25 | 0.2% | 3.5% | ||
| Q1 25 | 0.8% | 3.5% | ||
| Q4 24 | 2.5% | 4.0% | ||
| Q3 24 | 0.5% | 2.7% | ||
| Q2 24 | 0.5% | 4.7% |
现金转化率HCIOFIX
| Q1 26 | — | — | ||
| Q4 25 | 4.55× | — | ||
| Q3 25 | 0.41× | — | ||
| Q2 25 | 2.19× | — | ||
| Q1 25 | 2.32× | — | ||
| Q4 24 | 128.41× | — | ||
| Q3 24 | 18.33× | — | ||
| Q2 24 | -0.54× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HCI
暂无分部数据
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
